Recent studies propose using agonistic monoclonal antibodies targeting butyrophilin subfamily 3 member A1 (BTN3A1) to enhance Vδ2 T cell activation and cytotoxicity against tumor cells [1, 42–45]. The gene discussed is BTN3A1; the disease is neoplasm.